• AACR Annual Meeting 2014

    The annual meeting of the American Association for Cancer Research (AACR) highlights the latest and most exciting discoveries in every area of cancer research, providing opportunities for investigators from all over the world to meet, network, and forge new scientific interactions.

    The 105th AACR annual meeting was held from April 5 – 9, 2014, in San Diego, California. This year's annual meeting theme, "Harnessing Breakthroughs — Targeting Cures," reflected the great progress being made in cancer research as discoveries in the lab are translated into treatments in an increasingly targeted and precise manner.

    Along with the hundreds of invited talks, the annual meeting featured over 6,000 proffered papers by researchers from all over the world, including a number of papers and talks from Dana-Farber Cancer Institute researchers.

    Highlights

    News stories

    Dana-Farber scientists receive Stand Up To Cancer-Farrah Fawcett Foundation Grant for research in novel vaccine for HPV-associated cancers
    Dana-Farber researchers have received a three-year, $1.2 million research grant from Stand Up To Cancer (SU2C) and the Farrah Fawcett Foundation to lead a team in developing and testing new vaccines for patients with cancers linked to the human papillomavirus (HPV).

    Study identifies lung cancer patients likely to benefit from potential immune system-based therapy
    Investigators at Dana-Farber led by Leena Gandhi, MD, PhD, report a promising way of predicting which patients with non-small cell lung cancer (NSCLC) are most likely to benefit from a drug that frees up an immune system attack on tumor cells.

    Lectureship

    Researcher Levi A. Garraway, MD, PhDResearcher Levi A. Garraway, MD, PhD  

    The American Association for Cancer Research (AACR) and its Minorities in Cancer Research (MICR) membership group awarded Dana-Farber researcher and faculty member Levi A. Garraway, MD, PhD, with the Jane Cooke Wright Lectureship at the annual meeting.

    The AACR-MICR Jane Cooke Wright Lectureship was established in 2006 to give recognition to an outstanding scientist who has made meritorious contributions to the field of cancer research and who has, through leadership or by example, furthered the advancement of minority investigators in cancer research.

    Garraway, who is an associate professor of medicine in the Department of Medical Oncology at Harvard Medical School, presented his lecture, "The Cancer Genome in Biology, Therapy, and Drug Resistance," on Sunday, April 6, at 3:15 p.m. in the San Diego Convention Center.

    Elected fellows

    The American Association for Cancer Research (AACR) inducted its 2014 class of elected fellows of the AACR Academy at the AACR Annual Meeting 2014, including three Dana-Farber faculty.

    William G. Kaelin Jr., MD, professor of medicine, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Mass.; investigator, Howard Hughes Medical Institute

    David M. Livingston, MD, deputy director of the Dana-Farber Cancer Institute, chief of the Charles A. Dana Division of Human Cancer Genetics, and Emil Frei professor of genetics and medicine, Harvard Medical School, Boston, Mass.

    Frederick P. Li, MD, professor of clinical cancer epidemiology emeritus, Harvard School of Public Health; professor of medicine emeritus, Dana-Farber Cancer Institute, Boston, Mass.

    The AACR Academy is an entity within the AACR that recognizes those individuals who have made exceptional contributions to cancer research and/or cancer-related biomedical science. Only scientists whose work has had a major impact on the field are eligible for election as a fellow.

    Additional information

    Dana-Farber speakers at the AACR Annual Meeting 2014 

    Follow us on Twitter for additional information.

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms
  • Personalized Medicine Research

    • Barrett Rollins, MD, PhD and Neil Lindeman, MDLearn about Profile, a comprehensive somatic genotyping study that focuses on the development of targeted treatments for every person with cancer.
  • For Postdocs